Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression.

Cancer Immunology Microenvironment

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
15 Mar 2024
Historique:
received: 30 01 2023
revised: 16 01 2024
accepted: 06 02 2024
medline: 29 2 2024
pubmed: 29 2 2024
entrez: 29 2 2024
Statut: epublish

Résumé

Tissue-resident macrophages (TRMs) are abundant immune cells within pre-metastatic sites, yet their functional contributions to metastasis remain incompletely understood. Here, we show that alveolar macrophages (AMs), the main TRMs of the lung, are susceptible to downregulation of the immune stimulatory transcription factor IRF8, impairing anti-metastatic activity in models of metastatic breast cancer. G-CSF is a key tumor-associated factor (TAF) that acts upon AMs to reduce IRF8 levels and facilitate metastasis. Translational relevance of IRF8 downregulation was observed among macrophage precursors in breast cancer and a

Identifiants

pubmed: 38420590
doi: 10.1016/j.isci.2024.109187
pii: S2589-0042(24)00408-5
pmc: PMC10901102
doi:

Types de publication

Journal Article

Langues

eng

Pagination

109187

Informations de copyright

© 2024 Roswell Park Comprehensive Cancer Center.

Déclaration de conflit d'intérêts

M.O. has received research support from Alphageneron, AIM Therapeutics, Eli Lilly, and Pfizer. The other authors declare no competing interests.

Auteurs

Stephanie L Tzetzo (SL)

Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Elliot D Kramer (ED)

Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Hemn Mohammadpour (H)

Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Minhyung Kim (M)

Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Spencer R Rosario (SR)

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Han Yu (H)

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Melissa R Dolan (MR)

Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Chetan C Oturkar (CC)

Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Brian G Morreale (BG)

Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Paul N Bogner (PN)

Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Aimee B Stablewski (AB)

Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Fernando J Benavides (FJ)

Department of Epigenetics and Molecular Carcinogenesis, MD Anderson Cancer Center, Houston, TX 77030, USA.

Craig M Brackett (CM)

Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

John M L Ebos (JML)

Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Gokul M Das (GM)

Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Mateusz Opyrchal (M)

Department of Medicine, Indiana University, Indianapolis, IN 46202, USA.

Michael J Nemeth (MJ)

Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Sharon S Evans (SS)

Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Scott I Abrams (SI)

Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Classifications MeSH